temozolomide / Generic mfg. - LARVOL DELTA

Radiological Response to Capecitabine and Temozolomide in an Elderly Patient with Metastatic Leiomyosarcoma: A Case Report. (PubMed, J Clin Med) - "Following eight cycles of first-line gemcitabine plus docetaxel, the patient achieved stable disease without objective tumor shrinkage. Treatment was well tolerated, with no grade 3-4 toxicities. This case demonstrates a differential response to gemcitabine-based therapy and sensitivity to alkylating agents in LMS, supporting a more individualized, mechanism-driven treatment sequencing approach."

Journal • Hepatocellular Cancer • Leiomyosarcoma • Oncology • Sarcoma • Soft Tissue Sarcoma • Solid Tumor

Design and Evaluation of PLGA-Based Hybrid Nanoparticles for Nasal Paclitaxel Delivery: Formulation Optimization, Barrier Transport, and Cytotoxicity Assessment. (PubMed, ACS Omega) - "Cytotoxicity assays in U87-MG glioblastoma cells showed that HNP-PTX reduced cell viability more than both taxol and temozolomide (TMZ). These in vitro findings suggest HNP-PTX is a promising candidate for further in vivo evaluation as an intranasal formulation for glioblastoma treatment."

Journal • Brain Cancer • Glioblastoma • Glioma • Oncology • Solid Tumor

Safety and Efficacy of Sonodynamic Therapy Combined with Stupp Regimen in Controlling Postoperative Residual Lesions of Glioblastoma: A Prospective Pilot Phase I Study. (PubMed, Photodiagnosis Photodyn Ther) - "Integrating transcranial SDT with standard chemoradiotherapy and maintenance temozolomide is safe, feasible, and well tolerated in newly diagnosed GBM with residual disease. Encouraging preliminary efficacy signals warrant further evaluation in multi-center Phase II trials."

Journal • P1 data • Brain Cancer • Glioblastoma • Oncology • Solid Tumor

Selective remodeling of snoRNA and sdRNA biology in glioblastoma. (PubMed, Front Cell Dev Biol) - "These alterations converge on three recurrent cellular contexts: translational capacity, glucose and glycolipid metabolism, and survival under radiotherapy or temozolomide...SnoRNAs and sdRNAs should be viewed as an emerging regulatory layer in GBM rather than as established therapeutic targets. Future work should validate molecule-specific snoRNA and sdRNA axes in disease-relevant models and determine whether extracellular-vesicle snoRNAs provide reproducible readouts of treatment-associated cell states."

Journal • Review • Brain Cancer • Glioblastoma • Glioma • Metabolic Disorders • Oncology • Solid Tumor • TRIM24 • ZBTB7A

Rapid Administration Pilot for Infusing Dinutuximab (clinicaltrials.gov) - P2 | N=30 | Active, not recruiting | Sponsor: Children's Hospital Los Angeles | Phase classification: P1 ➔ P2 | N=11 ➔ 30 | Trial completion date: Jan 2026 ➔ Nov 2029 | Trial primary completion date: Jan 2026 ➔ Nov 2028

Enrollment change • Phase classification • Trial completion date • Trial primary completion date • Neuroblastoma • Oncology • Solid Tumor

AI-driven radiomics and radiogenomics: supporting the assessment and differentiation of pseudoprogression in cellular immunotherapy for glioblastoma. (PubMed, Front Immunol) - "Pseudoprogression (PsP), particularly following radiotherapy and combination therapy with temozolomide and new immunotherapies, may be falsely identified as true progression (TP) by conventional MRI, thus leading to premature termination of treatment or unnecessary intensification of therapy...In the future, many research groups will conduct multi-centre validation, standardize workflows, open-source reporting and release clinically interpretable models. The above ways can reduce the bias induced by PsP and improve differentiation between pseudoprogression and true progression to facilitate prompt treatment for most people."

IO biomarker • Journal • Review • Brain Cancer • Glioblastoma • Oncology • Solid Tumor

CDKN2A homozygous deletion defines a distinct treatment response pattern and therapeutic vulnerability in IDH-mutant astrocytoma (EANO 2026) - "CDKN2A-null cells showed increased sensitivity to temozolomide but reduced senescence and G1 arrest, with temozolomide and radiotherapy assays consistent with an increased potential for post treatment regrowth... CDKN2A HoD astrocytomas exhibit initial treatment sensitivity followed by rapid repopulation, supporting an "attack-and-arrest" therapeutic strategy to improve durability of response in this subgroup."

Astrocytoma • Brain Cancer • Oncology • Solid Tumor • CDKN2A • IDH1

INB-200: Fully enrolled phase 1 study of gene-modified autologous gamma-delta (γδ) T cells in patients with newly diagnosed glioblastoma multiforme (GBM) receiving maintenance temozolomide (TMZ). (ASCO 2024) - P1 | "γδ T cells successfully infused with peripheral TMZ-based lymphodepletion evidenced with near or below normal range T, B, and NK subsets for up to 1 year. The majority of dosed patients who received DRI exceeded the expected median PFS of 7 months (5.8-8.2 months) with Stupp alone and had manageable toxicity with a continued encouraging trend in PFS. Long-term follow-up for durability of PFS and OS continue."

Clinical • P1 data • Brain Cancer • Cardiovascular • CNS Disorders • CNS Tumor • Fatigue • Glioblastoma • Hematological Disorders • Hepatology • Infectious Disease • Nephrology • Oncology • Otorhinolaryngology • Pain • Solid Tumor • Thrombosis • Ventriculomegaly • MGMT • NKG2D

Abexinostat attenuates temozolomide-resistant glioma stem cells. (PubMed, Neuro Oncol) - "Abx reduced both DNA repair machinery and GSC markers by decreasing chromatin accessibility. Abx reduced tumor growth and mesenchymal GSCs in vitro and in vivo in GBM PDC and PDX models, supporting Abx's potential to prevent GSC-mediated therapy resistance and improve patient survival."

Journal • Brain Cancer • Glioblastoma • Glioma • Oncology • Solid Tumor • ALDH1A1 • ALDH1A3 • BMI1 • BRCA1 • CD44 • CHEK1 • KLF4 • MYC • RAD51

Temozolomide resistance in glioblastoma: Multidimensional networks, core signaling hubs, and targeted therapeutic strategies. (PubMed, Biochim Biophys Acta Mol Cell Res) - "It dissects signaling cascades of distinct resistance mechanisms and crosstalk between core signaling axes, and identifies key regulatory molecules and druggable targets for each resistance phenotype. It aims to provide a theoretical basis and novel insights for the development of emerging therapeutic strategies, including targeted therapy, immunomodulation, combination therapy, and nanodrug delivery, thereby promoting the establishment of multi-targeted and individualized precision medicine models and laying a foundation for breaking through the bottleneck of GBM chemoresistance and improving the survival prognosis of patients."

Journal • Review • Brain Cancer • Glioblastoma • Glioma • Immunology • Oncology • Solid Tumor • AMPK • mTOR • STAT3

High-Dose Methotrexate Containing Induction Chemotherapy Followed By Nivolumab Consolidation in Older (≥ 65) Patients with Previously Untreated Primary CNS Lymphoma (ASH 2023) - P1 | "Variations of the following regimens were used for induction: 43% R-MPV (rituximab, methotrexate, procarbazine, and vincristine) (43%), 29% MRT (methotrexate, rituximab, and temozolomide), 21% MR (methotrexate and rituximab), and 7% MATRix (methotrexate, cytarabine, thiotepa, and rituximab)... The current study demonstrates encouraging safety and clinical outcomes of nivolumab consolidation in older PCNSL patients who are deemed poor candidates for ASCT or WBI. No DLT was observed during the safety run-in phase, and there was no unexpected toxicity associated with nivolumab although 1 patient discontinued the study treatment due to Stevens-Johnson syndrome, a rare but known AE associated with nivolumab, after Cycle 1. Overall, nivolumab consolidation was associated with favorable survival rates in a group of patients with poor-risk PCNSL."

Clinical • Acute Kidney Injury • CNS Lymphoma • Fatigue • Hematological Disorders • Hematological Malignancies • Infectious Disease • Lymphoma • Nephrology • Neutropenia • Non-Hodgkin’s Lymphoma • Oncology • Primary Central Nervous System Lymphoma • Renal Disease • Septic Shock • Steven-Johnson Syndrome

Glioblastoma-primed astrocytes abrogate γδT and NK cell cytotoxicity against GBM tumors via secreted factors and direct targeting of immune cells in vitro (EANO 2026) - "Background: Glioblastoma (IDH WT, GBM) is one of the most aggressive and prevalent adult brain tumors, and despite several therapeutic options, including surgical resection, radiotherapy, and temozolomide chemotherapy, patients encounter a very poor prognosis... Targeting or reversing apoptotic pathways in tumor-infiltrated γδT and NK cells can have major implications for therapy design and can improve γδT and NK cell immune therapies for GBM patients."

Immune cell • Preclinical • Brain Cancer • Glioblastoma • Oncology • Solid Tumor

High-grade gliomas H3G34-mutant in pediatric and AYA population: a single center experience (EANO 2026) - "First-line chemotherapy included Nimotuzumab/Vinorelbine regimen (NV) (3/12), NV plus Temozolomide (TMZ) (4/12), TMZ alone (3/12), and TMZ plus Bevacizumab (1/12).Best response included partial response in 3/12 and stable disease in 1/12...At progression, one patient received re-irradiation and NV; 4/8 received second-line strategies, including TMZ plus Regorafenib (1/4), TMZ plus sirolimus (1/4), Nivolumab (1/4) and Bevacizumab (1/4), with limited impact on long-term outcomes... Although limited in size, this case series underscores the poor prognosis of HGG G34 in pediatric and young adult patients, characterized by infiltrative growth, restricted surgical resectability, and suboptimal response to current treatment modalities. These findings highlight the urgent need for the development of novel therapeutic strategies and more effective molecularly targeted approaches to address this rare yet highly aggressive malignancy."

Clinical • Brain Cancer • Glioma • High Grade Glioma • Oncology • Solid Tumor • CHEK2 • MSH3 • NBN • POLD1

A window-of-opportunity trial of mycophenolate mofetil and temozolomide in recurrent IDH-wildtype glioblastoma (SNO 2026) - No abstract available

Brain Cancer • Glioblastoma • Solid Tumor

The multifaced role of personality and its pathoplastic effect on the presentation and treatment of behavioral alterations in people with gliomas (EANO 2026) - "We conducted a cross-sectional study of 67 patients with IDH-wild-type glioblastoma assessed during concomitant radiotherapy (60 Gy) and temozolomide treatment...Personality and resilience contribute to how psychological distress is expressed in patients with glioblastoma, supporting a pathoplastic model. Early assessment of these factors may help guide personalized, phenotype-oriented psycho-oncological care during treatment."

Brain Cancer • Glioblastoma • Glioma • Oncology • Solid Tumor

Pharmacological Blockade of NMUR2 Suppresses Glioma Growth by Inhibiting STAT5-Mediated Transcription of Cell Cycle-associated Genes. (PubMed, Int J Biol Sci) - "Although temozolomide (TMZ) remains the standard chemotherapeutic agent for glioma, frequent recurrence and the development of therapeutic resistance continue to limit clinical benefit, highlighting the need for new molecular targets and treatment strategies...In addition, combination treatment with TMZ produced synergistic anti-tumor effects in glioma models. Collectively, our findings define a previously unrecognized NMUR2/Gαq/STAT5/PIM1-FOXM1 signaling axis in glioma and support pharmacological inhibition of NMUR2 as a potential therapeutic strategy."

Journal • Brain Cancer • Glioma • Oncology • Solid Tumor • FOXM1 • NMU • PIM1 • STAT5 • STAT5AWqe

A pilot induction regimen incorporating dinutuximab and sargramostim for the treatment of newly diagnosed high-risk neuroblastoma: A report from the Children's Oncology Group. (ASCO 2022) - P2 | "Chemoimmunotherapy including irinotecan, temozolomide, DIN and sargramostim (GM-CSF) in patients with recurrent or refractory neuroblastoma results in robust objective clinical responses. The administration of DIN and GM-CSF to COG Induction Cycles 3-5 for patients with newly-diagnosed high-risk neuroblastoma was tolerable and feasible. The objective response rate at EOI appears encouraging. This therapeutic regimen will be studied in a randomized phase 3 trial to further evaluate the efficacy of Induction phase chemoimmunotherapy for high-risk neuroblastoma."

Clinical • Hypotension • Neuroblastoma • Oncology • Pain • Solid Tumor • CSF2

Heat shock protein 90 inhibition synergizes with standard of care combination treatment of glioblastoma in preclinical models (EANO 2026) - "However, due to toxicity or insufficient efficacy, only TAS116 (pimitespib) has been approved for clinical use as monotherapy in advanced gastrointestinal tumors in Japan...Preclinical studies have demonstrated a synergistic anticancer effect of the Hsp90 inhibitor onalespib in combination with external beam radiotherapy (EBRT) in malignant gliomas, next to synergy of onalespib with temozolomide (TMZ)... Cell viability assays in U‑87 MG-WT, M059J, and M059K GBM models demonstrated nanomolar‑range EC₅₀ values for all tested Hsp90 inhibitors. Early triple‑combination experiments indicate a trend toward synergistic interactions among onalespib, TMZ, and EBRT. Ongoing in vitro experiments include cell viability analysis, clonogenic survival, and protein alterations following monotherapy, dual-, and triple-combination treatments using blood-brain barrier-penetrating Hsp90 inhibitors alongside TMZ and EBRT."

Preclinical • Brain Cancer • Glioblastoma • Oncology • Solid Tumor • CDC37

Integrating Collagen Tile Brachytherapy with External Beam Radiation and Temozolomide for Newly Diagnosed Glioblastoma: A Preliminary Report from a Feasibility Trial (ASTRO 2025) - P4 | "These findings support the feasibility of planning and starting EBRT in a timely manner after CTBT. A high proportion of patients initiated EBRT within the desired postoperative timeframe, which is the primary study aim of NCT05342883. The safety aim will be reported separately with longer follow up."

Brain Cancer • Glioblastoma • Oncology • Solid Tumor

Phase III Randomized Trial of Radiotherapy with Dual vs. Single Alkylator Chemotherapy (Temozolomide +/- Lomustine) in Newly Diagnosed MGMT Promoter Methylated Glioblastoma: Interim Results of NRG-BN011 (SNO 2026) - No abstract available

Clinical • P3 data • P3 data: top line • Brain Cancer • Glioblastoma • Solid Tumor • MGMT

Neoadjuvant camrelizumab plus apatinib and temozolomide for resectable stage II/III acral melanoma: The CAP 03-NEO trial. (ASCO 2025) - P2 | "Stage 1 results of CAP 03-NEO demonstrated the potential of neoadjuvant camrelizumab, apatinib and temozolomide in pts with resectable stage II/III AM. The pNR result support advancing to stage 2 to further assess the efficacy and safety of this regimen in pts with stage III disease."

Clinical • Constipation • Gastroenterology • Gastrointestinal Disorder • Melanoma • Oncology • Solid Tumor

Dual-drug delivery system based on cubosomes for glioblastoma therapy: electrochemical, structural and biological characterization. (PubMed, Nanoscale Adv) - "In this study, we developed a dual-drug delivery system based on lipid liquid-crystalline cubic phases (LCPs) co-loaded with temozolomide (TMZ) and doxorubicin (DOX). The structural properties of the nanoparticles were characterized using small-angle X-ray scattering (SAXS) and dynamic light scattering (DLS). Biological evaluation demonstrated that combination treatment with a standard concentration of TMZ and a lower concentration of DOX resulted in improved therapeutic outcomes in A172 glioblastoma-derived and HeLa cell lines."

Journal • Brain Cancer • Glioblastoma • Oncology • Solid Tumor

AMPK γ-Subunit Isoform Switching Governs Temozolomide Resistance and Survival in Glioblastoma. (PubMed, Cells) - "Our findings reveal that AMPK γ-subunit isoform switching is a previously unrecognized metabolic adaptation that drives TMZ resistance in GBM. Targeting the γ2-specific complex or preventing this isoform transition represents a promising therapeutic strategy to overcome chemoresistance in malignant gliomas."

Journal • Brain Cancer • Glioblastoma • Glioma • High Grade Glioma • Oncology • Solid Tumor • AMPK

Androgen Receptor signaling pathway supports glioblastoma cell proliferation and sensitivity to chemotherapy (EANO 2026) - "Using both in vitro and in vivo models (GBM patient-derived cell lines -GBM-PDCL- and orthotopic GBM mouse xenografts), we investigated cell viability/proliferation, gene expression profiles, and sensitivity to temozolomide before and after pharmacological modulation of the AR signaling pathway using dihydrotestosterone and enzalutamide. Male sex is an independent prognostic factor for survival in our local GBM cohort, a finding that was validated in the TCGA-GBM dataset. Our clinical and biological findings support a role for the AR signaling pathway in GBM cell proliferation, viability, and response to chemotherapy. These results provide a rationale for the clinical evaluation of AR signaling pathway inhibitors in GBM."

Brain Cancer • Glioblastoma • Oncology • Solid Tumor

Pesticides in glioblastoma : preliminary evidence on carcinogenesis and resistance to radiochemotherapy (EANO 2026) - "Despite standard radiochemotherapy with temozolomide, relapse remains inevitable due to resistance mechanisms, potentially worsened by pesticide exposure... These preliminary findings provided promising evidence supporting the involvement of pesticides in both tumor development and resistance to oncological treatments. A prospective epidemiological study and in vivo experiments using a mouse model are currently underway."

Brain Cancer • Glioblastoma • Oncology • Solid Tumor